0%

est. 2Y upside i

HealthcareSeries A

Enable collaborates with the world’s leading researchers to construct detailed and searchable maps of complex diseases, making possible the exploration, navigation, and discovery of underlying biologi

Rank

#2046

Sector

Biotechnology

Est. Liquidity

~0Y

Data Quality

Data: Low

Enable Medicine was acquired in December 2024, so any equity grant today would be in the context of the acquisition.

Last updated: July 21, 2026

Bull (0%)0%

Acquisition completed; no further upside from standalone equity.

Base (100%)0%

Company acquired by General Inception on Dec 12, 2024; equity likely converted at acquisition price, assumed at last round valuation $178M.

Bear (0%)0%

Acquisition terms unknown; downside limited as deal closed.

Est. time to liquidity~0.0 years

Preference Stack Risk

high

Funding Intensity

0%

Total funding of $63.6M represents 35.7% of the last round valuation, creating significant preference overhang.

Dilution Risk

high

No recent raise; but given age of round and acquisition, further dilution unlikely.

Secondary Liquidity

none

No secondary market activity detected; acquisition provides the only liquidity event.

Engineering — 5 roles

Marketing — 4 roles

Success & Services — 3 roles

View all 16 open roles at Enable →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Enable's data — designed to show you've done your homework.

  • 1

    “How does Enable Medicine's platform differentiate from Recursion and Schrödinger?”

  • 2

    “What is the revenue run rate and key customer metrics post-acquisition?”

  • 3

    “What is the equity structure now under General Inception? Is there a liquidity path for employees?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.